NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

CALABASAS, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced the closing of its acquisition of an intellectual property portfolio featuring artificial intelligence, 3D bioprinting, and quantum modeling technologies. This move significantly fortifies NeOnc’s drug discovery engine and helps accelerate its mission to develop therapies for complex neurological cancers.

Read more at globenewswire.com